See more : RENK Group AG (R3NK.F) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaCyte Biotech, Inc. (PMCB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaCyte Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Emdeki Utama Tbk (MDKI.JK) Income Statement Analysis – Financial Results
- i-CABLE Communications Limited (ICABF) Income Statement Analysis – Financial Results
- Kurimoto, Ltd. (5602.T) Income Statement Analysis – Financial Results
- Pernod Ricard SA (PDRDY) Income Statement Analysis – Financial Results
- Petlife Pharmaceuticals, Inc. (PTLF) Income Statement Analysis – Financial Results
PharmaCyte Biotech, Inc. (PMCB)
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.16K | 66.56K | 126.00K | 262.93K | 653.13K | 1.19M | 1.17M | 537.04K | 86.37K | 2.38K | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.62K | 19.38K | 32.10K | 228.66K | 427.41K | 266.20K | 171.01K | 0.00 | 41.40K | 780.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54K | 47.18K | 93.89K | 34.27K | 225.72K | 923.75K | 998.65K | 537.04K | 44.97K | 1.60K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.89% | 70.88% | 74.52% | 13.03% | 34.56% | 77.63% | 85.38% | 100.00% | 52.07% | 67.27% | 0.00% | 0.00% |
| Research & Development | 407.43K | 468.54K | 690.94K | 916.25K | 301.22K | 460.05K | 2.00M | 1.18M | 1.41M | 3.48M | 323.50 | 0.00 | 0.00 | 9.21K | 492.46K | 473.51K | 412.88K | 133.84K | 119.01K | 1.11M | 1.41M | 0.00 | 0.00 |
| General & Administrative | 4.79M | 5.99M | 3.70M | 2.71M | 3.53M | 3.64M | 4.98M | 3.26M | 4.67M | 9.99M | 18.11M | 1.58M | 1.99M | 462.22K | 1.24M | 5.20M | 0.00 | 0.00 | 6.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 230.50K | 872.20K | 106.41K | 11.15K | 10.83K | 411.72K | 594.34K | 0.00 | 0.00 | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.12M | 5.99M | 3.70M | 2.71M | 3.53M | 3.64M | 4.98M | 3.26M | 4.67M | 10.22M | 18.98M | 1.69M | 2.00M | 473.05K | 1.65M | 5.79M | 4.26M | 4.47M | 7.75M | 3.10M | 313.95K | 32.13K | 0.00 |
| Other Expenses | 0.00 | 202.00K | -4.28K | -1.19K | -40.00 | 33.40K | 152.59K | 2.52M | 10.54K | 3.34M | -5.90M | 2.59K | 1.22M | 103.90K | 0.00 | 4.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.85K |
| Operating Expenses | 8.52M | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 13.70M | 18.98M | 1.69M | 2.00M | 482.25K | 2.14M | 6.27M | 4.67M | 4.61M | 7.87M | 4.21M | 1.72M | 32.13K | 29.85K |
| Cost & Expenses | 6.52M | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 13.70M | 18.98M | 1.70M | 2.02M | 514.36K | 2.37M | 6.70M | 4.94M | 4.78M | 7.87M | 4.25M | 1.72M | 32.13K | 29.85K |
| Interest Income | 3.40M | 1.94M | 157.65K | 3.05 | 0.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09K | 0.00 | 0.00 | 0.00 | 0.00 | 14.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 509.00 | 3.05K | 453.00 | 0.00 | 0.00 | 1.54K | 1.19K | 4.94K | 21.05K | 154.42K | 241.25K | 171.66K | 292.56K | 27.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 492.05K | -5.89M | 2.59K | 24.66K | 40.69K | 114.91K | 28.83K | 6.38K | 1.35K | 488.00 | 23.26K | 0.00 | 0.00 | 0.00 |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -3.83M | 0.00 | 0.00 | -4.44M | 0.00 | -9.92M | -27.23M | -1.68M | -1.63M | -388.36K | -2.11M | -5.99M | -3.78M | -3.61M | -7.33M | -1.72M | -1.73M | -32.13K | -29.85K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,830.35% | -3,328.88% | 388.91% | 607.14% | -922.67% | -308.99% | -308.83% | -1,049.52% | -4,810.34% | -72,213.26% | 0.00% | 0.00% |
| Operating Income | -6.52M | -6.46M | -4.39M | -3.62M | -3.83M | -4.10M | -6.98M | -4.44M | -6.07M | -13.70M | -18.98M | -1.68M | -1.95M | -388.36K | -2.11M | -6.04M | -3.75M | -3.61M | -7.34M | -4.16M | -1.72M | -32.13K | -29.85K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,851.65% | -2,928.55% | -308.23% | -802.09% | -925.09% | -315.07% | -308.42% | -1,365.85% | -4,819.57% | -72,213.26% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.85M | 2.14M | 152.85K | 71.75K | -493.00 | 33.40K | 152.59K | -1.54K | 9.35K | 2.84M | -8.27M | 86.26K | 49.87K | -837.69K | -3.88M | 471.00 | -42.72K | -6.79K | -1.76M | -114.04K | 1.73M | 0.00 | 0.00 |
| Income Before Tax | 333.76K | -4.32M | -4.24M | -3.55M | -3.83M | -4.07M | -6.83M | -4.44M | -6.06M | -10.85M | -27.25M | -1.60M | -1.66M | -1.23M | -5.70M | -6.03M | -3.82M | -3.60M | -9.03M | -4.15M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,142.29% | -2,491.16% | -973.08% | -2,167.62% | -923.10% | -320.62% | -307.90% | -1,682.09% | -4,801.87% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.94M | -153.36K | 3.05K | 453.00 | -33.40K | -152.59K | -4.44K | -4.88K | 4.94K | 19.96K | 154.42K | -49.87K | 1.01M | 3.88M | -471.00 | 42.72K | 6.79K | 2.05M | 114.04K | 1.72M | 32.13K | 29.85K |
| Net Income | 333.76K | -4.32M | -4.09M | -3.55M | -3.83M | -4.07M | -6.83M | -4.44M | -6.06M | -10.85M | -27.25M | -1.60M | -1.90M | -1.40M | -5.99M | -6.04M | -3.79M | -3.61M | -9.39M | -4.28M | -1.72M | -32.13K | -29.85K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,142.29% | -2,853.62% | -1,109.32% | -2,278.89% | -925.02% | -318.66% | -309.00% | -1,747.61% | -4,951.60% | -72,375.79% | 0.00% | 0.00% |
| EPS | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.89 | -12.09 | -23.11 | -70.06 | -5.43 | -7.60 | -5.98 | -29.81 | -44.86 | -33.86 | -33.36 | -102.95 | -61.74 | -27.40 | -0.55 | -0.51 |
| EPS Diluted | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.88 | -12.08 | -23.11 | -70.06 | -5.43 | -7.60 | -5.98 | -29.81 | -44.86 | -33.86 | -33.36 | -102.95 | -61.74 | -27.40 | -0.55 | -0.51 |
| Weighted Avg Shares Out | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 733.40K | 645.76K | 563.54K | 501.60K | 469.79K | 389.01K | 294.12K | 249.97K | 233.68K | 200.97K | 134.68K | 112.01K | 108.34K | 91.16K | 69.27K | 62.95K | 58.70K | 58.70K |
| Weighted Avg Shares Out (Dil) | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 733.40K | 646.08K | 563.82K | 501.85K | 469.79K | 389.01K | 294.12K | 249.97K | 233.68K | 200.97K | 134.68K | 112.01K | 108.34K | 91.16K | 69.27K | 62.95K | 58.70K | 58.70K |
PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced further results from a third test of biocompatibility of its CypCaps™...
PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech announces that its encapsulation material does not alter cellular DNA.
PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of a second U.S. Food and Drug Administration (FDA)-required...
PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech releases more positive results from the FDA required biocompatibility tests. The clinical trial capsules passed the tests.
PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the first test results of the biocompatibility studies of its CypCaps™...
PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech announces positive results of one of the biocompatibility studies required by the FDA.
7 Penny Stocks Waiting on The FDA for Rocket Fuel
News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPlace.
PMCB Stock: Why It Is Trading Higher Today
The stock price of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) is trading at over 20% pre-market today. This is why it happened.
After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble
There's no denying that PMCB stock has lost much of its value over the years. However, recent developments could catalyze a price resurgence.
PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be presenting at the H.C....
Source: https://incomestatements.info
Category: Stock Reports